SearchCME LoginCE Login Show Cart
NACE: National Association For Continuing Education 866-266-6223 9a am to 5 pm EST Mon-Fri
CME Course Description
Login to view
Course Activities.

CME Live Virtual Conferences

Go Back


Author Affiliation
Co-Course Director
Gregg Sherman, MD
Family Practice
Northwest Heart and Health
Margate, FL

Deborah Paschal, CRNP
Clinical Nurse Practitioner
Cardiothoracic Surgery Division
Penn-Presbyterian Medical Center
Philadelphia, PA

Medical Writer
Cedric Nazareth, MBBS

Kimberly Carter, MS, PA-C,
HUP Department of MedicineGastroenterology Division Philadelphia, PA

Gerald W. Dryden, MD, MSPH, MSc, AGAF, FASGE
Professor of Medicine and Bioengineering, Director of Clinical Research, Division of Gastroenterology, Hepatology and Nutrition
University of Louisville
Louisville, KY

: Inflammatory Bowel Disease: Diagnosis, Treatment and Management
Activity/Course #:
: NCMEB292x

: $25.00
Release/Start Date:
: Feb 08 2017
Expiration Date:
: Feb 07 2018
: Gastroenterology
Target Audience:
: Primary Care Providers
: Monograph
Estimated Time To Complete CME Activity:
: 1.0 Hours
: 0
Hardware/Software Requirements:
This monograph will provide information about diagnosis and management of Inflammatory Bowel Disease (IBD) for optimal outcomes. Case studies are presented throughout the monograph which will highlight “Treat to Target” management strategies for patients failing therapy including getting drug and drug antibody levels prior to deciding on increasing or changing medications and recognition of patients at highest risk for progression to surgery that require more aggressive therapy. Awareness of steroid sparing treatment strategies, like direct colonic delivery of medications for patients with progressive symptoms and predictors of risk of progression to surgery will be discussed along with testing protocols to clarify source and severity of disease flares and the role of fecal calprotectin levels. Emphasis is put on communication with patients and families regarding quality-of-life issues and the risks and benefits associated with use of biologic agents as a therapeutic option to allow for medication compliance.

Learning Objective(s):

After completing this program participants should be able to:

  1. Recognize patients with inflammatory bowel disease (IBD) who are at risk for complications, as determined by clinical indicators.
  2. Apply individualized treatment strategies to clinical IBD presentations to maximize outcomes while minimizing toxicity.
  3. Identify patients who are at high risk of complications from IBD specifically targeting new treatment goals including mucosal healing and deep remission.
  4. Implement treat-to-target therapy where appropriate to optimize benefits from IBD treatment options and facilitate adherence.

How To Obtain Your CME Certificate

  1. Register for the course at
  2. View the content.
  3. Complete and submit the post-test and evaluation.
  4. A minimum passing score of 80% must be earned on the post-test in order to complete the CME activity.
  5. Print your CME certificate.
Sponsored and Certified By
National Association for Continuing Education
Accreditation Designation Statement
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 1.0 contact hour of continuing education (which includes 0.5 hours of pharmacology).
Faculty Disclosure Policy
Policy on Faculty and Provider Disclosure: It is the policy of the National Association for Continuing Education to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the National Association for Continuing Education are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosures are provided below.

Kimberly Carter, MS, PA-C has no financial relationships with commercial interests to disclose.

Gerald W. Dryden, MD, MSPH, MSc, AGAF, FASGE serves on the speaker’s bureaus of Abbvie, Takeda, EnteraHeatlh and Salix. Dr. Dryden also conducts contracted research for Abbvie, Johnson & Johnson, Merck, Takeda, Pfizer, and Genentech.

Gregg Sherman, MD, Co-Course Director, has no relationships to disclose.

Deborah Paschal, CRNP, Co-Course Director, has no relationships to disclose.

Cedric Nazareth, Medical Writer, has no relationships to disclose.

Harvey C. Parker, Ph.D., Activity Planning Committee, has the following relationships to disclose: co-owner of Specialty Press, Inc. and Health Link Systems, Inc.

Michelle Frisch, MPH, Activity Planning Committee, has no relationships to disclose.

Alan Goodstat, LCSW, Activity Planning Committee, has no relationships to disclose.

Sheila Lucas, CWEP, Activity Planning Committee, has no relationships to disclose.

Cheryl C. Kay, Activity Planning Committee, has no relationships to disclose.
Commercial Support
No commercial support was received for this activity.